The pharmaceutical industry faces a difficult challenge. Drug development takes years, costs billions of dollars, and carries a high risk of failure. Researchers must identify promising compounds, test their safety, conduct clinical trials, and secure regulatory approval before a medicine reaches patients. As a result, companies constantly seek technologies that can reduce costs and improve outcomes. In this context, many professionals ask: What is the role of generative AI in drug discovery?

Generative artificial intelligence is transforming how scientists discover and develop new medicines. Unlike traditional software, generative AI can create novel molecular structures, predict biological interactions, and assist researchers in designing drug candidates. Consequently, it has emerged as a powerful tool in modern pharmaceutical research.

However, the rise of AI drug discovery also raises important legal and regulatory questions. Issues related to intellectual property, data protection, accountability, transparency, and regulatory compliance are becoming increasingly significant. Therefore, understanding both the scientific and legal dimensions of this technology is essential.

This article explores what is the role of generative AI in drug discovery, how it works, its benefits, challenges, and the legal implications that pharmaceutical companies, researchers, and policymakers must address.

Understanding Generative AI in Drug Discovery

Before examining what is the role of generative AI in drug discovery, it is important to understand what generative AI means.

Generative AI refers to machine learning systems that can generate new content based on patterns learned from existing data. While many people associate generative AI with text and images, its applications extend far beyond content creation. In the pharmaceutical sector, generative AI can design entirely new molecular compounds with desired biological properties.

Traditionally, researchers screened thousands or even millions of molecules to identify a potential drug candidate. This process required extensive laboratory work and significant financial investment. In contrast, generative AI models can analyze large biological datasets and propose promising molecules within a much shorter period.

As a result, AI drug discovery enables researchers to move from trial-and-error methods toward more targeted and efficient drug development strategies.

What Is the Role of Generative AI in Drug Discovery?

The central role of generative AI is to accelerate and optimize the drug development process. When discussing what is the role of generative AI in drug discovery, several key functions stand out.

Designing Novel Drug Molecules

One of the most important contributions of generative AI is its ability to create new molecular structures. Researchers can specify desired characteristics such as effectiveness, safety, or target specificity. The AI system then generates potential compounds that meet those requirements.

Consequently, scientists gain access to innovative molecules that may never have emerged through conventional methods. This capability significantly expands the range of potential therapeutic options.

Identifying Drug Targets

Drug discovery begins with identifying biological targets associated with diseases. Generative AI can analyze genetic, proteomic, and clinical data to uncover relationships that human researchers might overlook.

Therefore, AI drug discovery helps scientists identify new targets for treating complex conditions such as cancer, Alzheimer’s disease, and rare genetic disorders.

Predicting Molecular Behavior

Another important aspect of what is the role of generative AI in drug discovery involves predicting how molecules will behave inside the human body.

AI models can estimate factors such as toxicity, absorption, metabolism, and efficacy. As a result, researchers can eliminate unsuitable compounds early in the development process, saving both time and resources.

Optimizing Existing Drugs

Generative AI is not limited to creating new medicines. It can also improve existing drugs by suggesting structural modifications that enhance performance or reduce side effects.

Accordingly, pharmaceutical companies can extend the value of existing drug portfolios while improving patient outcomes.

Supporting Personalized Medicine

Modern healthcare increasingly focuses on individualized treatment. Generative AI can analyze patient-specific data and help identify therapies that are most likely to be effective for particular groups or individuals.

Thus, AI drug discovery supports the broader goal of precision medicine.

Benefits of Generative AI in Drug Discovery

The growing adoption of generative AI is driven by several significant advantages. As pharmaceutical companies seek faster and more cost-effective ways to develop medicines, generative AI continues to reshape the research landscape. Understanding what is the role of generative AI in drug discovery becomes easier when examining the practical benefits it delivers throughout the drug development process.

Faster Research and Development

Traditional drug discovery often requires more than a decade because researchers must screen thousands of compounds before identifying a viable candidate. However, generative AI dramatically accelerates this process by creating and evaluating potential molecules in a fraction of the time. Instead of relying solely on laboratory-based trial and error, scientists can use AI-generated predictions to prioritize the most promising compounds.

Moreover, AI models analyze vast datasets simultaneously, allowing researchers to identify patterns and relationships that would otherwise take years to uncover. As a result, AI drug discovery shortens research timelines and helps bring life-saving treatments to patients much sooner.

Lower Development Costs

Drug development costs can exceed billions of dollars, making efficiency a critical concern for pharmaceutical companies. Generative AI reduces expenses by minimizing the number of unsuccessful experiments and optimizing resource allocation. Rather than testing countless compounds in laboratories, researchers can focus on candidates that demonstrate strong potential from the outset.

Furthermore, AI-driven insights reduce the need for repetitive screening processes. Consequently, companies can lower operational costs while maintaining high research standards. This financial efficiency makes AI drug discovery an attractive investment for both established pharmaceutical firms and emerging biotechnology companies.

Improved Success Rates

A significant percentage of drug candidates fail during preclinical and clinical development. Generative AI helps address this challenge by predicting toxicity, efficacy, and molecular behavior before extensive testing begins. Therefore, researchers can identify risks at an earlier stage and eliminate unsuitable compounds quickly.

Additionally, AI systems continuously learn from new data, improving prediction accuracy over time. As a result, AI drug discovery increases the likelihood of advancing successful candidates through the development pipeline.

Enhanced Innovation

Generative AI explores vast chemical spaces that human researchers cannot easily navigate. Consequently, it can generate entirely novel molecular structures that may lead to breakthrough therapies. This capability expands the possibilities for treating complex diseases and rare medical conditions.

For this reason, many organizations view AI drug discovery as a strategic tool for driving pharmaceutical innovation and maintaining a competitive advantage.

Better Disease Understanding

AI systems can process complex biological, genetic, and clinical datasets at an unprecedented scale. As a result, researchers gain deeper insights into disease mechanisms and progression. These insights support the development of more targeted and effective therapies.

Furthermore, a better understanding of diseases allows scientists to identify new drug targets and improve treatment strategies. Therefore, what is the role of generative AI in drug discovery extends beyond molecule generation to advancing medical knowledge itself.

Legal Risks of AI Drug Discovery: Key Challenges for the Pharmaceutical Industry

Artificial intelligence is transforming pharmaceutical research by accelerating drug development, reducing costs, and improving the identification of potential drug candidates. However, while AI drug discovery offers significant benefits, it also introduces complex legal risks that companies, researchers, and regulators must address. As AI-generated insights increasingly influence scientific decisions, legal accountability and regulatory compliance become more important than ever.

Intellectual Property and Patent Risks

Uncertainty Over Inventorship

One of the most significant legal risks in AI drug discovery relates to intellectual property rights. Patent laws in most jurisdictions recognize only human inventors. When an AI system generates a novel molecule or identifies a new therapeutic use, questions arise regarding who should be credited as the inventor.

This uncertainty can create disputes between pharmaceutical companies, AI developers, and researchers. It may also affect the validity and enforceability of patent applications.

Patent Eligibility Challenges

Patent offices require inventions to be novel, useful, and non-obvious. AI-generated compounds may raise concerns about whether the inventive step originated from human creativity or machine-generated analysis. Consequently, organizations may face difficulties obtaining patent protection for AI-assisted discoveries.

Data Privacy and Confidentiality Risks

Use of Sensitive Health Data

AI systems often rely on large datasets containing patient records, genomic information, and clinical trial data. The use of such information creates substantial privacy risks.

Organizations must comply with applicable data protection laws and ensure that personal data is collected, processed, and stored lawfully. Failure to comply can result in regulatory investigations, financial penalties, and reputational damage.

Data Breaches and Cybersecurity Threats

Pharmaceutical datasets are valuable targets for cybercriminals. If AI systems process sensitive medical information without adequate security measures, companies may face legal liability for data breaches and unauthorized disclosures.

Regulatory Compliance Risks

Lack of Clear Regulatory Standards

Regulatory frameworks governing AI in healthcare continue to evolve. Many jurisdictions have not yet established comprehensive rules specifically addressing AI-generated drug candidates.

As a result, pharmaceutical companies may face uncertainty regarding compliance obligations. Regulatory expectations can also vary across countries, making international drug development more complex.

Validation and Explainability Requirements

Regulators require scientific evidence demonstrating the safety and effectiveness of new drugs. AI-generated predictions alone are insufficient for regulatory approval.

Companies must validate AI outputs through laboratory testing and clinical trials. Additionally, regulators may require transparency regarding how AI systems reach specific conclusions. Failure to provide adequate documentation can delay approvals and increase compliance risks.

Liability and Accountability Concerns

Responsibility for AI-Generated Errors

A major legal challenge involves determining liability when AI-generated recommendations prove inaccurate or harmful. If an AI-designed compound causes unexpected adverse effects, multiple parties could potentially be held responsible.

These parties may include:

• Pharmaceutical manufacturers
• AI software developers
• Data providers
• Research institutions

Without clear legal standards, allocating responsibility can become difficult and lead to costly litigation.

Product Liability Exposure

Even when AI assists in development, pharmaceutical companies generally remain responsible for ensuring product safety. Therefore, reliance on AI does not eliminate traditional product liability risks.

Contractual and Licensing Risks

Data and Software Licensing Issues

AI drug discovery often depends on third-party datasets, algorithms, and cloud-based platforms. Companies must ensure that they possess appropriate licenses and usage rights.

Improper use of proprietary data or software may result in breach-of-contract claims, intellectual property disputes, and financial penalties.

Vendor Dependency Risks

Many pharmaceutical organizations rely on external AI providers. Poorly drafted contracts may create uncertainty regarding ownership of AI-generated outputs, confidentiality obligations, and liability allocation.

Ethical and Bias-Related Risks

Algorithmic Bias

AI models learn from historical data. If training datasets contain biases, the resulting outputs may produce unequal outcomes across different patient populations.

Such issues can trigger regulatory scrutiny, discrimination claims, and reputational harm.

Lack of Transparency

Healthcare decisions require a high level of trust. If AI systems operate as “black boxes” without clear explanations, regulators and stakeholders may question the reliability of AI-generated discoveries.

AI drug discovery presents enormous opportunities for pharmaceutical innovation, but it also creates significant legal risks. Intellectual property disputes, privacy concerns, regulatory uncertainty, liability challenges, contractual issues, and ethical considerations all require careful attention. To mitigate these risks, pharmaceutical companies should implement strong governance frameworks, maintain regulatory compliance, conduct thorough validation processes, and establish clear contractual protections. A proactive legal strategy will be essential as AI continues to reshape the future of drug development.

Ethical Considerations in Generative AI Drug Discovery

Ethics and law often intersect in emerging technologies. Therefore, any discussion of what is the role of generative AI in drug discovery must also address the ethical challenges associated with its use. While generative AI offers remarkable opportunities for innovation, stakeholders must ensure that its deployment remains fair, transparent, and socially responsible. Ethical oversight plays a critical role in ensuring that AI drug discovery benefits patients without creating new forms of inequality or risk.

Bias in Training Data

AI systems learn from existing datasets, making data quality a fundamental ethical concern. If training datasets contain demographic, geographic, or socioeconomic biases, AI models may produce biased outcomes. Consequently, certain patient groups may receive less accurate predictions or fewer treatment options.

For example, if datasets primarily represent specific populations, the resulting drug candidates may not perform equally well across diverse groups. Therefore, organizations involved in AI drug discovery must use diverse and representative datasets. Additionally, they should conduct regular audits to identify and eliminate hidden biases. By doing so, researchers can improve fairness and ensure that AI-driven medical innovations serve broader populations.

Transparency and Trust

Public confidence remains essential in healthcare and pharmaceutical research. However, many generative AI systems operate through complex algorithms that can be difficult to explain. When researchers, regulators, or patients cannot understand how a system concludes, trust may decline.

Therefore, transparency should remain a core principle in AI drug discovery initiatives. Companies should document AI processes, explain decision-making methods, and provide clear evidence supporting AI-generated findings. Moreover, transparent practices help regulators evaluate safety and effectiveness more efficiently. As a result, greater openness strengthens public trust and promotes responsible innovation.

Access and Equity

Generative AI has the potential to revolutionize healthcare worldwide. Nevertheless, unequal access to advanced technologies may widen existing healthcare disparities. Wealthy organizations and developed nations often possess greater access to AI infrastructure, data resources, and research capabilities.

Consequently, patients in lower-income regions may not benefit equally from AI-driven breakthroughs. Policymakers and healthcare leaders must therefore develop strategies that promote equitable access to innovations generated through AI drug discovery. Such efforts can help ensure that technological advancements improve global health outcomes rather than deepen existing inequalities.

Accountability and Human Oversight

Although AI can generate valuable insights, human experts must remain responsible for critical decisions. Researchers, pharmaceutical companies, and healthcare professionals cannot transfer accountability entirely to algorithms.

Therefore, organizations should establish clear governance structures that define responsibility for AI-generated recommendations. Human oversight helps identify errors, validate findings, and ensure compliance with ethical and legal standards. In this way, accountability remains a cornerstone of responsible AI drug discovery.

Patient Safety and Informed Decision-Making

Patient welfare must remain the highest priority in pharmaceutical innovation. While generative AI can accelerate research, companies must thoroughly test AI-generated drug candidates before introducing them into clinical settings.

Furthermore, stakeholders should communicate the role of AI in the development process openly and accurately. This transparency enables informed decision-making among regulators, healthcare providers, and patients. Ultimately, understanding what is the role of generative AI in drug discovery requires balancing innovation with a strong commitment to patient safety, ethical responsibility, and public trust.

Real-World Examples of Generative AI in Drug Discovery

The growing impact of generative AI becomes clearer when examining real-world success stories. Several biotechnology and pharmaceutical companies have already demonstrated what is the role of generative AI in drug discovery by using advanced AI systems to identify drug targets, design novel compounds, and accelerate clinical development. These examples highlight how AI drug discovery is moving from theory to practical application.

Insilico Medicine

Insilico Medicine stands among the most recognized pioneers in generative AI-driven drug development. The company uses AI platforms to identify biological targets and generate potential drug candidates for various diseases. Notably, Insilico developed an AI-designed drug candidate for idiopathic pulmonary fibrosis in a significantly shorter timeframe than traditional methods typically require.

Moreover, the company demonstrated that generative AI can reduce the time needed to move from target identification to preclinical testing. This achievement provides strong evidence of what is the role of generative AI in drug discovery and how AI can streamline early-stage pharmaceutical research. As a result, Insilico has become a leading example of innovation in AI drug discovery.

Exscientia

Exscientia has transformed drug development by integrating artificial intelligence into every stage of the discovery process. The company collaborates with major pharmaceutical organizations to design optimized drug candidates with greater speed and precision.

Furthermore, Exscientia gained attention for developing AI-designed molecules that advanced into clinical trials. By leveraging machine learning and generative AI, the company reduces the need for extensive trial-and-error experimentation. Consequently, its success demonstrates how AI drug discovery can improve efficiency while lowering research costs and accelerating innovation.

Recursion Pharmaceuticals

Recursion Pharmaceuticals combines artificial intelligence, automation, and large-scale biological data analysis to discover new therapies. The company uses AI to analyze millions of biological images and identify hidden patterns associated with diseases and potential treatments.

Additionally, Recursion’s data-driven approach allows researchers to uncover novel drug targets that traditional methods may overlook. Through strategic partnerships with leading pharmaceutical and technology companies, the organization continues to expand the practical applications of AI drug discovery.

Together, these companies illustrate what is the role of generative AI in drug discovery in real-world settings. Their achievements show that generative AI is not merely a future possibility but an active force reshaping pharmaceutical innovation, accelerating research timelines, and improving the development of life-saving therapies.

Regulatory Framework Governing AI Drug Discovery

As generative AI becomes increasingly integrated into pharmaceutical research, regulatory oversight plays a crucial role in ensuring safety, efficacy, transparency, and accountability. Although AI drug discovery accelerates innovation, regulatory authorities continue to require rigorous scientific validation before approving any new medicine. Therefore, understanding the regulatory framework is essential when examining what is the role of generative AI in drug discovery from a legal perspective.

U.S. Food and Drug Administration (FDA)

The U.S. Food and Drug Administration (FDA) remains one of the most influential regulatory authorities in the pharmaceutical sector. While the FDA has not created a separate approval pathway exclusively for AI-generated drugs, it evaluates AI-assisted discoveries under existing drug approval standards.

Moreover, the FDA emphasizes transparency, data integrity, and scientific reliability throughout the development process. Companies using generative AI must demonstrate that their drug candidates meet established safety and efficacy requirements through preclinical studies and clinical trials. Consequently, AI-generated predictions cannot replace scientific evidence. Instead, they must support and strengthen the overall research process. As AI drug discovery evolves, the FDA continues to develop guidance on the responsible use of artificial intelligence in healthcare and pharmaceutical innovation.

European Medicines Agency (EMA)

The European Medicines Agency (EMA) has also recognized the growing role of artificial intelligence in drug development. The agency supports innovation while ensuring that pharmaceutical companies maintain high standards of patient safety and regulatory compliance.

Furthermore, the EMA encourages organizations to adopt transparent and trustworthy AI systems. Companies must provide sufficient documentation explaining how AI models contribute to drug discovery decisions. This approach helps regulators assess the reliability of AI-generated outcomes. Therefore, the EMA plays a critical role in shaping the future regulatory landscape surrounding what is the role of generative AI in drug discovery within the European Union.

Central Drugs Standard Control Organisation (CDSCO)

In India, the Central Drugs Standard Control Organisation (CDSCO) serves as the primary regulatory authority overseeing pharmaceutical products and clinical research. Although India has not yet introduced specific regulations exclusively governing AI drug discovery, existing drug approval requirements continue to apply to AI-assisted innovations.

Additionally, India’s broader digital governance initiatives and emerging AI policies indicate a growing focus on regulating advanced technologies responsibly. As the Indian pharmaceutical industry increasingly adopts generative AI, the CDSCO will likely play a central role in establishing standards related to validation, safety, data governance, and compliance.

Collectively, these regulatory bodies demonstrate that while AI drug discovery offers transformative opportunities, robust oversight remains essential to ensure ethical, safe, and legally compliant pharmaceutical innovation.

Impact of AI Drug Discovery on Pharmaceutical Law

The rapid growth of AI drug discovery is reshaping the legal landscape of the pharmaceutical industry. As companies increasingly rely on generative AI to identify drug targets, design molecules, and optimize research processes, several areas of law require careful consideration. Therefore, understanding what is the role of generative AI in drug discovery also requires examining its impact on pharmaceutical law and regulatory governance.

Patent Law

• Generative AI challenges traditional patent frameworks because patent laws generally recognize human inventors rather than artificial intelligence systems.
• When AI generates a novel drug compound, legal questions arise regarding inventorship, ownership, and patent eligibility.
• Furthermore, patent offices must determine whether AI-assisted inventions satisfy novelty, utility, and inventive-step requirements.
• Consequently, pharmaceutical companies must develop robust intellectual property strategies to protect innovations created through AI drug discovery.

Contract Law

• AI-driven drug development often involves collaborations between pharmaceutical companies, technology providers, research institutions, and data vendors.
• Therefore, contract law plays a critical role in defining ownership rights, confidentiality obligations, licensing arrangements, and liability allocation.
• Well-drafted agreements help prevent disputes regarding AI-generated outputs and proprietary research data.
• As a result, organizations engaged in AI drug discovery must establish clear contractual frameworks before initiating partnerships.

Data Protection Law

• Generative AI relies heavily on large datasets, including clinical records, genomic information, and patient health data.
• Consequently, organizations must comply with applicable data protection and privacy regulations when collecting, processing, and storing sensitive information.
• Failure to safeguard patient data may result in regulatory investigations, financial penalties, and reputational damage.
• Therefore, data governance remains a critical legal consideration in what is the role of generative AI in drug discovery.

Product Liability Law

• Pharmaceutical companies remain responsible for ensuring the safety and effectiveness of AI-assisted drug candidates.
• If an AI-generated drug causes unexpected adverse effects, courts may examine whether developers exercised reasonable care during the development process.
• Additionally, liability disputes may involve pharmaceutical manufacturers, AI developers, and research partners.
• Thus, organizations must implement rigorous testing and risk-management procedures throughout the AI drug discovery lifecycle.

Regulatory Compliance

• Regulatory authorities such as the FDA, EMA, and CDSCO require scientific validation of all drug candidates, regardless of AI involvement.
• Companies must maintain transparency, document AI-generated findings, and comply with evolving regulatory standards.
• Moreover, regulators increasingly expect explainable and trustworthy AI systems in healthcare.
• Consequently, regulatory compliance will remain a central legal challenge as AI drug discovery continues to transform pharmaceutical innovation.

The Future of Generative AI in Drug Discovery

The future of AI drug discovery appears exceptionally promising as technological advancements continue to transform pharmaceutical research. As researchers develop more sophisticated generative AI models, the industry will likely experience faster innovation, greater efficiency, and improved treatment outcomes. Therefore, understanding what is the role of generative AI in drug discovery will become increasingly important for scientists, legal professionals, policymakers, and healthcare organizations.

Accelerating the Discovery of Novel Therapies

Generative AI will continue to enhance the ability of researchers to design innovative molecular structures for complex diseases. Unlike traditional methods, AI systems can rapidly analyze vast chemical spaces and identify promising compounds that may otherwise remain undiscovered. Consequently, pharmaceutical companies can develop treatments for rare diseases, cancer, neurological disorders, and other challenging conditions more efficiently. As a result, AI drug discovery will play a central role in expanding therapeutic possibilities.

Strengthening Collaboration Across Industries

The future of drug development will depend heavily on collaboration. Pharmaceutical companies, technology firms, academic institutions, and regulatory authorities are already forming strategic partnerships to maximize the potential of generative AI. Moreover, these collaborations encourage knowledge sharing, improve research quality, and accelerate innovation. By combining scientific expertise with advanced AI capabilities, stakeholders can address both technical and regulatory challenges more effectively.

Advancing Regulatory and Legal Frameworks

As the use of AI expands, governments and regulatory agencies will continue developing comprehensive governance frameworks. These regulations will provide greater clarity regarding intellectual property rights, data privacy obligations, transparency requirements, and liability standards. Furthermore, clear legal guidelines will encourage responsible innovation while protecting public interests. Therefore, legal professionals will play an increasingly important role in advising organizations involved in AI drug discovery.

Enabling Personalized and Precision Medicine

Generative AI will significantly contribute to the growth of personalized healthcare. By analyzing genetic, clinical, and lifestyle data, AI systems can help researchers develop therapies tailored to specific patient groups. Consequently, treatments may become more effective while reducing adverse side effects. This shift toward precision medicine represents one of the most transformative aspects of what is the role of generative AI in drug discovery.

Improving Global Healthcare Outcomes

Ultimately, the future of AI drug discovery extends beyond faster research and commercial success. Generative AI has the potential to improve access to innovative treatments, support public health initiatives, and address unmet medical needs worldwide. As technology, regulation, and ethical standards continue to evolve together, generative AI will become an indispensable tool in shaping the future of healthcare and pharmaceutical innovation.

Conclusion

Generative AI is reshaping the pharmaceutical industry by enabling faster, more efficient, and more innovative drug development. It can design novel molecules, identify promising drug targets, predict molecular behavior, and support personalized medicine. As a result, AI drug discovery offers significant opportunities to improve healthcare outcomes and reduce development costs.

Nevertheless, the technology also raises complex legal questions involving intellectual property, data ownership, privacy, regulatory oversight, and liability. Therefore, organizations must adopt a balanced approach that combines technological innovation with strong legal compliance and ethical responsibility.

Ultimately, the answer to what is the role of generative AI in drug discovery extends beyond scientific advancement. Generative AI serves as both a transformative research tool and a catalyst for legal and regulatory evolution. As the pharmaceutical industry continues to embrace AI-driven innovation, the legal framework governing these technologies will play a decisive role in shaping their future impact on global healthcare.

References

1. Artificial Intelligence (AI) Applications in Drug Discovery and Development – PMC
2. The Future of Pharmaceuticals: Artificial Intelligence in Drug Discovery and Development – ScienceDirect
3. Generative Artificial Intelligence in Drug Discovery: Basic Framework and Applications – Frontiers in Pharmacology
4. Artificial Intelligence in Drug Discovery and Development – Wiley Online Library
5. The Future of AI Regulation in Drug Development – NIH PMC
6. FDA Draft Guidance on AI in Drug Development Explained
7. AI-Driven Drug Discovery: A Comprehensive Review – ACS Omega
8. Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products – FDA
9. Generative AI Applications in Drug Discovery: Accelerating Innovation in Pharmaceuticals
10. From Algorithm to Medicine: AI in the Discovery and Development of Drugs – MDPI
11. Explainable Artificial Intelligence for Drug Discovery and Development: A Comprehensive Survey
12. Artificial Intelligence for Drug Discovery: Are We There Yet?
13. Generative Chemistry: Drug Discovery with Deep Learning Generative Models
14. US and European Regulators Set Principles for Good AI Practice in Drug Development – Reuters
15. AI-Driven Drug Discovery Picks Up as FDA Pushes to Reduce Animal Testing – Reuters